Standard Precautions and Post Exposure Prophylaxis

1. Standard Precautions and Post Exposure Prophylaxis Unit 17 HIV Care and ART: A Course for Healthcare Professionals

2. Learning Objectives • Describe the basic principles and procedures of standard precautions • Identify the risks of HIV, HCV, and HBV seroconversion following accidental occupational exposures • List the management steps of occupational exposure • Describe the principles of HIV post-exposure prophylaxis

3. Case study • Abebech is a 32 year-old nurse. She came to the ART clinic after she sustained a needle stick while providing an injection to a hospitalized patient. She thinks that the patient is HIV positive and she is requesting HIV post-exposure prophylaxis • What measures are important for preventing this problem in the future? • What further information is needed to manage this patient?

4. Occupational Exposure Risk

5. Estimated Pathogen-Specific Seroconversion Rate Per Exposure for Occupational Needlestick Injury . AETC http://depts.washington.edu/hivaids

6. Type of Exposure Involved in Transmission of HIV to Health Care Workers AETC http://depts.washington.edu/hivaids

7. Source of HIV Involved in HIV Transmission to Health Care Worker AETC http://depts.washington.edu/hivaids

8. Risk Factors for HIV Transmission with Occupational Exposure to HIV-Infected Blood

9. Other Possible Risk Factors • Hollow bore vs solid bore • No documented cases to date of seroconversion from suture needles • Glove use • 50% decrease in volume of blood transmitted • Mucous membrane exposure

10. HIV in the Environment • How long does HIV live outside the body? • HIV does not survive well in the environment • When HIV-infected blood or body fluids dry, the theoretical risk of environmental transmission is essentially zero • No reports of environmental transmission

11. Standard Precautions

12. Standard Precautions • Definition • Standards developed to prevent exposure and transmission of disease in occupational setting • Provide guidance for the safe handling of infectious material • Formerly referred to as Universal Precautions. “Universal” means everyone, everywhere, always

13. Components of Standard Precautions • Hand washing – Key step in limiting nosocomial spread of disease • Use protective barriers when indicated • Gloves: mucus membranes, body fluids, broken skin • Goggles: procedures • Gowns/masks: procedures

14. Components of Standard Precautions (2) • Sharps and waste - handle with gloves and dispose in designated containers • Needles • Scalpels • Suture material • Bandages • Dressings • Anything contaminated with any body fluid

15. Rules to Follow While Disposing Sharps • Do not recap needles! • Put containers within arms reach • Use adequate light source when treating patients • Wear heavy-duty gloves when transporting sharps • Incinerate used needles to a sufficient temperature to melt • Keep sharps out of reach of children

16. Components of Standard Precautions (3) • Re-usable instruments - must be thoroughly disinfected • Speculums • Surgical tools • Thermometers • Immunizations • Hepatitis A and B

17. Recommended Antiseptic Solutions • Ethyl alcohol, 70% • Chlorhexidine, 2-4% (e.g. Hibtane, Hibiscrub) • Chlorhexidine gluconate and cetrimide, at least 2% (e.g. Savlon*) • Iodine tincture, 3% • Iodophores, 7.5-10% (e.g. Betadine) • Chlorozylenol in alcohol, 0.5-3.75%, (e.g. Dettol*) *Use undiluted

18. Recommended Disinfectants • Chlorine, 0.5% (Barkina) • Sedex and Ghion brands contain 5% Chlorine, dilute for use • Glutaraldehyde, 2-4% (e.g. Cidex) • Formaldehyde, 8% • Hydrogen peroxide, 6% • Soak the instrument for 20 minutes after decontamination and cleaning

19. Management of Occupational Exposure

20. Wound Care • Gently wash wounds with soap and water (don’t scrub vigorously) • Allow wounds to bleed freely • Irrigate exposed mucosal surfaces with sterile saline

21. Post Exposure Prophylaxis • Definition: • Use of therapeutic agent to prevent establishment of infection following exposure to pathogen • Roles in Occupational Exposure: • HIV prevention • HBV prevention

22. HIV PEP for Occupational Exposure • Overview • Limited data (animal) • Better to err on side of treatment • Exposed patient must be tested for HIV prior to PEP • Start immediately after exposure • Duration 28 days

23. Decision-making Tools for PEP • Source code (SC) • Risk assessment of the source patient • SC 1, SC 2, SC Unknown • Exposure code (EC) • Risk assessment of exposure type • EC 1, EC 2, EC 3

24. Step 1: Does This Patient Need HIV PEP? Source patient Unknown / Unwilling to get tested* HIV - HIV + High back-ground risk Low back-ground risk No PEP PEP No PEP *CDC recom: usually PEP unnecessary; consider use if source patient is high risk

25. HIV Negative HIV Positive Asymptomatic/high CD4 = HIV SC 1 Advanced disease,primary infection or low CD4 =HIV SC 2 HIV Status Unknown or Source Unknown = HIV SC Unknown No PEP Step 2: Determine HIV Status Code of Source (HIV SC)

26. Exposure on Mucous membrane or broken skin Exposure on Intact Skin Percutaneous Exposure Determine Volume Determine Severity NoPEP Few drops, short duration, SMALL = EC 1 Several drops/long duration/major blood splash LARGE = EC 2 Solid, superficial Scratch LESS SEVERE = EC 2 Hollow needle, deep Puncture MORE SEVERE = EC 3 Step 3: Type of Exposure: Determine the Exposure Code

27. Step 4: Determine PEP Regimen

28. Step 4: Determine PEP Regimen (2) • Less Severe: Solid needle, superficial injury • More Severe: Large-bore hollow needle, deep punture, visible blood on device, or needle used in patient's artery or vein • HIV Class 1: Asymptomatic or HIV RNA less than 1500 copies/ml • HIV Class 2: Symptomatic HIV infection, AIDS, acute seroconversion, or known high HIV RNA

29. HIV Post Exposure Prophylaxis • 2 drug regimen • Zidovudine plus lamivudine (combivir) • Stavudine plus Lamivudine • Tenofovir plus lamivudine • 3 drug regimen • LPV/r or Indinivr or Nelfinavir plus NRTI backbone • Efavirez plus NRTI backbone • Consider resistance potential of source patient • Don’t use NVP (hepatotoxicity)

30. HIV PEP - When to Start • As soon as possible! • U.S. Public Health Service Guidelines recommends prompt initiation of PEP (within hours of exposure), but does not rule out consideration of PEP even if more than 36 hours have elapsed since the exposure • Animal data show no benefit when treatment is delayed 24-36 hours • Most experts use 72 hour window limit

31. The Early Stages of HIV Infection Cell free HIV CD40—CD40 T-cell Immature Dendritic cell PEP Skin or mucosa Via lymphatics or circulation Burst of HIV replication 24 hours 48 hours HIV co-receptors, CD4 + chemokine receptor CC5 Mature Dendritic cell in regional LN undergoes a single replication, which transfers HIV toT-cell • Selective of macrophage-tropic HIV

32. HIV PEP - When to Stop • Timing is unclear • Animal studies suggest better efficacy with 28 days of PEP when compared with shorter duration of therapy

33. Current PEP Policy in Ethiopia • Emphasis is on standard precautions • Individual ART programs may access and distribute PEP free of charge

34. Case Study 1 • 27 year-old female nurse presents to OPD for evaluation of needle stick injury 2 days ago from a diabetic lancet • Source patient (SP): 35 year-old male, HIV+ • Discussion: • What do we need to know about the source patient and exposure in order to manage this nurse? • Would you offer her PEP? If so, which agents?

35. Additional Information • The SP has been taking AZT/3TC/NVP (1st regimen) for one year. • He was WHO stage II prior to starting ART, and is currently in good health • The SP’s most recent CD4 count was 200; his initial CD4 before starting ART was 180 • Viral load 2 months ago was 60,000 • How does this information influence the choice of PEP regimen?

36. Case Study 1 - Questions • What is her risk for contracting HIV? • What factors influence this risk? • Is it too late to start PEP? • Which regimen(s) should be considered? • What follow-up should be arranged?

37. Case Study 1: PEP Options • Source patient’s high-level viremia despite HAART suggests that he is either not taking his medications, or that he has developed resistance to his regimen • Resistance assay is not performed in Ethiopia – therefore must reason around patterns of anticipated resistance to SP’s regimen • If resistance has developed, would suspect resistance to lamivudine and zidovudine • May have NNRTI cross resistance as well

38. Case Study 1: PEP Options • High viral load of source patient would warrant use of a three drug PEP regimen • One reasonable PEP regimen: didanosine + tenofovir + lopinavir/ritonavir

39. Case Study 2 • 24 year-old dental technician splashed in the eye during dental procedure 3 hours ago • Source patient: 33 year-old male, co-infected with HIV and HCV • What else do you need to know?

40. Blood? Saliva? Sweat? Feces? Spinal fluid? Pleural fluid? Pus? Urine? Which Fluids are Potentially Infectious for HIV?

41. Blood Saliva Sweat Feces Spinal fluid Pleural fluid Pus Urine Which Fluids are Potentially Infectious for HIV? (2)

42. Case Study 2 – cont. • Saliva was visibly bloody - in fact, it was mostly blood that splashed her • She rinsed out her eye immediately • Source patient has never taken antiretrovirals, has a CD4 count of “about 500” and a viral load of 20,000 last time it was checked. • The exposed patient is 8 weeks pregnant

43. Case Study 2 – Questions • Discuss: • What are your PEP recommendations? • How does her pregnancy affect your decision making?

44. PEP in Pregnancy • Most antiretrovirals class B or C in pregnancy • Antiretroviral Pregnancy Registry has not detected increased teratogenic risk for ARVs in general, nor specifically for AZT and 3TC, in the first trimester1 • Avoid efavirenz (anencephaly in monkeys), amprenavir (ossification defects in rabbits), and, in late term, indinavir (hyperbilirubinemia) • Avoid combination d4T and ddI • Theoretically higher risk of vertical transmission with primary HIV infection

45. Case Study 2 - cont. • The patient starts AZT/3TC/Nelfinavir • 3 days later she calls complaining of headache, congestion, an itchy rash, and URI symptoms • What further information is needed for managing this patient?

46. Case 2 – cont. • Exam: • VS: T 99.0 R 14 P 78 BP 134/76 • Gen - alert, tired-appearing, no acute distress • HEENT - hyperemic nasal mucosa with frontal sinus tenderness; pharynx is also red • Neck - 3 cm. left ant cervical lymph node • Lungs, cardiac, abdomen: normal • Neuro: normal • Skin: urticarial rash on trunk and legs; no ulcerations

47. Case 2 – Questions • What is the most likely diagnosis? • How would you manage this patient?

48. Primary HIV Infection • Flu-like or mono-like illness often accompanied by a rash1 • Onset typically 2-6 weeks following exposure, but high variability • Symptoms generally resolve spontaneously in 1-3 wks (corresponding with VL reduction) • Treatment of PHI with antiretroviral therapy may have significant long-term benefit3

49. 1 mil HIV RNA 100,000 + HIV RNA HIV-1 Antibodies _ 10,000 Ab 1,000 Exposure 100 Symptoms 10 0 14 21 28 7 Days PHI: Diagnostic Testing Image courtesy of The Center for AIDS Information & Advocacy, www.centerforaids.org

50. Could She Have Primary HIV Infection? • Primary HIV Infection less likely • Only three days since the exposure • Presence of nasal congestion • Rash is urticarial • However, would not be unreasonable to check an HIV viral load to rule out PHI